Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07845500
Starting soon Phase 3

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

NCT07845500 · tracked via the Priya Life Science USA tracker
Sponsor
Pfizer
Phase
Phase 3
Started
2026-10-01
Last updated
2026-09-29

Condition(s) studied

ObesityOverweight and/or ObesityOverweightTreatment Of Obesity

Investigational drug(s) / intervention(s)

Semaglutide →Tirzepatide →Berobenatide →

Semaglutide: Participants will receive Semaglutide administered subcutaneously.

Tirzepatide: Participants will receive Tirzepatide administered subcutaneously.

Berobenatide: Participants will receive berobenatide solution for injection as subcutaneous injection.

Study summary

The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes.

Participants will be in the study for about 11 months.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Aged ≥18 years. * Currently taking semaglutide or tirzepatide for obesity management. Exclusion Criteria: * Diagnosis of any form of diabetes. * History of acute or chronic pancreatitis. * Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
University of Alabama at Birmingham Birmingham Alabama
Suncoast Clinical Research New Port Richey Florida
Monroe Biomedical Research Louisville Kentucky
Aa Mrc Llc Flint Michigan
Clinical Research Professionals Chesterfield Missouri
Mercury Street Medical Group, PLLC Butte Montana
Accellacare - Wilmington Wilmington North Carolina
Velocity Clinical Research, Mt. Auburn Cincinnati Ohio

On this site

📄 Ozempic (semaglutide) drug profile → 📄 Mounjaro (tirzepatide) drug profile →

More Pfizer trials in the USA

Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease Starting soon
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia Recruiting
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Active, not recruiting
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489 Active, not recruiting
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised Recruiting

Other trials for the same condition

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight Recruiting
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight Active, not recruiting
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity Active, not recruiting
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight Active, not recruiting
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07845500 on ClinicalTrials.gov ↗ ← All trials in the USA